VIB-VUB spin-off Animab, which is developing a new class of orally administered antibodies for animal health, announced the successful closing of its Series A round. The proceedings will be used to bring its lead product to market and to expand the pipeline of antibody products in animal health. The investment round was led by the venture capital fund Qbic III with participation from existing investors among which V-Bio Ventures and VIB. The spin-off is based on research from professor henri de greve at the VIB-VUB Han Remaut Lab.
Read more in De Tijd
Read more on VIB News